Syntis Bio operates as a late-stage preclinical company that develops oral therapies for obesity, diabetes, and rare diseases.
Syntis Bio has raised $33.0M in total funding. The most recent round was Series A. The last funding was announced in July 2025.
Syntis Bio's investors include Safar Partners, Cerity Partners Ventures, Cerberus Capital Management, National Institutes of Health, Bold Capital Partners.
Syntis Bio is headquartered in Boston, United States.
Syntis Bio operates as a late-stage preclinical company that develops oral therapies for obesity, diabetes, and rare diseases.
Syntis Bio is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Syntis Bio — Funding & Investors." VCBacked, July 1, 2025, https://www.vcbacked.co/company/syntis-bio. Accessed July 19, 2026.
VCBacked. (2025). Syntis Bio — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/syntis-bio
{{cite web |title=Syntis Bio — Funding & Investors |url=https://www.vcbacked.co/company/syntis-bio |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated